Hsbc Holdings PLC Has $134,000 Stock Position in Geron Corporation $GERN

Hsbc Holdings PLC reduced its position in shares of Geron Corporation (NASDAQ:GERN) by 69.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 86,528 shares of the biopharmaceutical company’s stock after selling 198,519 shares during the quarter. Hsbc Holdings PLC’s holdings in Geron were worth $134,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in GERN. Sowell Financial Services LLC acquired a new position in Geron during the 1st quarter worth approximately $43,000. GF Fund Management CO. LTD. acquired a new position in Geron during the 4th quarter worth approximately $45,000. 111 Capital acquired a new position in Geron during the 4th quarter worth approximately $52,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Geron during the 1st quarter worth approximately $63,000. Finally, Crestline Management LP acquired a new position in Geron during the 4th quarter worth approximately $64,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group assumed coverage on Geron in a report on Thursday, July 10th. They set a “sell” rating and a $1.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Geron has an average rating of “Moderate Buy” and a consensus price target of $4.19.

Geron Stock Performance

Shares of GERN opened at $1.40 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87. The stock has a 50 day moving average price of $1.34 and a two-hundred day moving average price of $1.47. The firm has a market capitalization of $893.23 million, a P/E ratio of -10.77 and a beta of 0.63. Geron Corporation has a 52 week low of $1.09 and a 52 week high of $4.83.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $49.04 million during the quarter, compared to analyst estimates of $47.30 million. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.Geron’s quarterly revenue was up 5455.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.10) earnings per share. Equities analysts forecast that Geron Corporation will post -0.25 earnings per share for the current fiscal year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.